Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribose (Furanose) SCHEMBL4391872 | 0.81 | ADA (0.41) | ADA | |
| Ribose (Furanose) SCHEMBL27484456 | 0.81 | ADA (0.41) | ADA | |
| Ribose (Furanose) SCHEMBL5199714 | 0.81 | ADA (0.41) | ADA | |
| 2-Aminopurine SCHEMBL1507729 | 0.81 | ALDH1A1 (0.55) | — | |
| Purine SCHEMBL27672877 | 0.80 | — | — | |
| Hypoxanthine SCHEMBL4367641 | 0.78 | LMNA (0.39) | — | |
| SCHEMBL98133 | 0.77 | HSD17B10 (0.38) | — | |
| SCHEMBL9142303 | 0.77 | LMNA (0.38) | — | |
| Adenine SCHEMBL593934 | 0.77 | PI4KA (0.54) | — | |
| Mercaptopurine Anhydrous SCHEMBL1998389 | 0.77 | LMNA (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103788160-A | (2R,5R)-5-phosphoryl methoxy-2-(2-substituted adenine-9-yl)-2,5-dihydrofuran nucleoside analog as well as preparation method and application thereof | UNIV ZHENGZHOU | 2014-05-14 | — | — | CN | claimed |
| US-20090318556-A1 | BIOMARKERS FOR DETECTING RADIATION EXPOSURE: METHODS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2009-12-24 | — | — | US | claimed |
| EP-0036145-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1985-05-29 | — | — | EP | claimed |
| CN-109136314-A | The method for synthesizing 2 '-deoxidation -2- amino adenosines using Michigan's Klebsiella | 新乡拓新药业股份有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-107083366-A | Express adoptive immunity cell of hirudin and its production and use | 何向锋 | 2017-08-22 | — | — | CN | disclosed |
| CN-103788160-A | (2R,5R)-5-phosphoryl methoxy-2-(2-substituted adenine-9-yl)-2,5-dihydrofuran nucleoside analog as well as preparation method and application thereof | UNIV ZHENGZHOU | 2014-05-14 | — | — | CN | disclosed |
| US-20090318556-A1 | BIOMARKERS FOR DETECTING RADIATION EXPOSURE: METHODS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2009-12-24 | — | — | US | disclosed |
| US-20090299049-A1 | Bicyclic Compounds and Their Use | REPLIZYME LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-1984455-A2 | BICYCLIC COMPOUNDS AND THEIR USE | THE UNIVERSITY OF YORK (GB) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007091056-A2 | BICYCLIC COMPOUNDS AND THEIR USE | THE UNIVERSITY OF YORK (GB) | 2007-08-16 | — | — | WO | disclosed |
| CN-1832743-A | dosage form comprising AG013736 | AGOURON PHARMA (US) | 2006-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318556-A1 | BIOMARKERS FOR DETECTING RADIATION EXPOSURE: METHODS AND USES THEREOF | OGG1, UNG, HPRT1 | TREH 854/4885ADA 777/4885 |
| US-20090299049-A1 | Bicyclic Compounds and Their Use | ERCC4, PARP1, ERCC5 | TREH 2974/4885ADA 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.